Market news

On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cash. The $10.9 billion buyouts immediately fold Apogee’s promising inflammatory and immunology (I&I) pipeline into AbbVie’s commercial engine. On the exact same day, AbbVie separately reported positive Phase 3 Cervino trial results for its […]

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion.

AbbVie (ABBV) said Thursday that it has completed its acquisition of Apogee Therapeutics (APGE), val

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

Detailed price information for Biogen Inc (BIIB-Q) from The Globe and Mail including charting and trades.

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

The pharmaceutical company hopes that another big-time acquisition will pay off.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

Apogee Therapeutics stock has delivered a very strong run over the past few years, yet the valuation checks currently lean expensive, which raises the question of how much of that optimism is already in the price. Apogee Therapeutics has returned roughly 5.5x over the past 3 years, which is a very large gain that can leave limited room if expectations ease. Expectations around the company’s ability to convert its pipeline into durable revenue streams can support the current share price. At...

Here is how Apogee Therapeutics Inc. (APGE) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.

There's no need to panic.

Henderson's disposition included a 20,000-share open-market sale and a 75,046-share charitable gift.

Apogee Therapeutics (APGE) has attracted fresh attention after recent trading data showed sharp share price moves over the past month. This has prompted investors to reassess this clinical stage biotech’s risk and return profile. See our latest analysis for Apogee Therapeutics. At a latest share price of $133.57, Apogee Therapeutics has seen a 57.14% 30 day share price return and a 76.26% year to date share price return, while the 1 year total shareholder return sits at 246.31%. This...